Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Marre, M; Shaw, J; Brändle, M; Bebakar, WM; Kamaruddin, NA; Strand, J; Zdravkovic, M; Le, Thi TD; Colagiuri, S; De Loredo, L; Waitman, J; Litwak, L; Rodriguez, M; Vines, G; Maffei, L; Issa, C; Lowy, A; Bartley, P; Kamp, M; Shaw, J; ... (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic medicine, 2009(26(3)), pp. 268-78. Chichester: Wiley 10.1111/j.1464-5491.2009.02666.x

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Christ, Emanuel

ISSN:

0742-3071

Publisher:

Wiley

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:14

Last Modified:

04 May 2014 23:24

Publisher DOI:

10.1111/j.1464-5491.2009.02666.x

Web of Science ID:

000264163800011

URI:

https://boris.unibe.ch/id/eprint/32624 (FactScience: 197861)

Actions (login required)

Edit item Edit item
Provide Feedback